Core Insights - The company, Guangdong Marubi Biotechnology Co., Ltd., reported a robust growth in profitability for the third quarter of 2025, with significant acceleration in growth momentum [1] Financial Performance - From January to September 2025, the company achieved a net profit attributable to shareholders of 244 million yuan, maintaining steady growth despite a high base from the previous year [1] - The third quarter net profit attributable to shareholders reached 69.4816 million yuan, with a year-on-year growth rate of 11.59%, indicating a notable improvement compared to the cumulative growth rate for the first three quarters [1] - Basic earnings per share for the third quarter were 0.18 yuan, reflecting a year-on-year increase of 12.5%, which outpaced the net profit growth rate, showcasing the company's ability to enhance shareholder value [1] Growth Momentum - The company not only maintained stable profit levels in the first three quarters of 2025 but also demonstrated strong growth momentum in both profit and earnings per share, with both metrics exceeding 10% year-on-year growth in the third quarter [1]